Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluCAB-Prime for Haploidentical HSCT in Aplastic Anemia
NCT03955601Phase 2Unknown
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in aplastic anemia, sponsored by National Institute of Blood and Marrow Transplant. Primary endpoint: Overall Survival at 1 year. Status: unknown.
02
Drugs
busulfan
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT03955601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955601.